These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 21129061)
41. The value of MGMT promote methylation and IDH-1 mutation on diagnosis of pseudoprogression in patients with high-grade glioma: A meta-analysis. Zhou M; Niu C; Jia L; He H Medicine (Baltimore); 2019 Dec; 98(50):e18194. PubMed ID: 31852075 [TBL] [Abstract][Full Text] [Related]
42. Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T. Paech D; Windschuh J; Oberhollenzer J; Dreher C; Sahm F; Meissner JE; Goerke S; Schuenke P; Zaiss M; Regnery S; Bickelhaupt S; Bäumer P; Bendszus M; Wick W; Unterberg A; Bachert P; Ladd ME; Schlemmer HP; Radbruch A Neuro Oncol; 2018 Nov; 20(12):1661-1671. PubMed ID: 29733378 [TBL] [Abstract][Full Text] [Related]
43. Continuing the search for MR imaging biomarkers for MGMT promoter methylation status: conventional and perfusion MRI revisited. Gupta A; Omuro AM; Shah AD; Graber JJ; Shi W; Zhang Z; Young RJ Neuroradiology; 2012 Jun; 54(6):641-3. PubMed ID: 22006425 [No Abstract] [Full Text] [Related]
44. Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors. Bady P; Delorenzi M; Hegi ME J Mol Diagn; 2016 May; 18(3):350-361. PubMed ID: 26927331 [TBL] [Abstract][Full Text] [Related]
45. Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas. Siegal T Adv Tech Stand Neurosurg; 2016; (43):91-108. PubMed ID: 26508407 [TBL] [Abstract][Full Text] [Related]
46. Molecular Characteristics of Thalamic Gliomas in Adults. Wang T; Niu X; Gao T; Zheng L; Qiu Y; Mao Q J Mol Neurosci; 2021 Aug; 71(8):1598-1604. PubMed ID: 33523385 [TBL] [Abstract][Full Text] [Related]
47. IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Minniti G; Scaringi C; Arcella A; Lanzetta G; Di Stefano D; Scarpino S; Bozzao A; Pace A; Villani V; Salvati M; Esposito V; Giangaspero F; Enrici RM J Neurooncol; 2014 Jun; 118(2):377-383. PubMed ID: 24748470 [TBL] [Abstract][Full Text] [Related]
48. Comparison of Radiomics Analyses Based on Different Magnetic Resonance Imaging Sequences in Grading and Molecular Genomic Typing of Glioma. Huang WY; Wen LH; Wu G; Hu MZ; Zhang CC; Chen F; Zhao JN J Comput Assist Tomogr; 2021 Jan-Feb 01; 45(1):110-120. PubMed ID: 33475317 [TBL] [Abstract][Full Text] [Related]
49. Bridging science and clinical practice: how to use molecular markers when caring for a patient with brain cancer. Rosenfeld MR Am Soc Clin Oncol Educ Book; 2013; ():108-13. PubMed ID: 23714471 [TBL] [Abstract][Full Text] [Related]
50. Diagnostic Accuracy of Immunohistochemistry in Detecting MGMT Methylation Status in Patients with Glioma. Sahara N; Hartanto RA; Yoshuantari N; Dananjoyo K; Widodo I; Malueka RG; Dwianingsih EK Asian Pac J Cancer Prev; 2021 Dec; 22(12):3803-3808. PubMed ID: 34967558 [TBL] [Abstract][Full Text] [Related]
51. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. Kessler T; Sahm F; Sadik A; Stichel D; Hertenstein A; Reifenberger G; Zacher A; Sabel M; Tabatabai G; Steinbach J; Sure U; Krex D; Grosu AL; Bewerunge-Hudler M; Jones D; Pfister SM; Weller M; Opitz C; Bendszus M; von Deimling A; Platten M; Wick W Neuro Oncol; 2018 Feb; 20(3):367-379. PubMed ID: 29016808 [TBL] [Abstract][Full Text] [Related]
52. Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial. Collins VP; Ichimura K; Di Y; Pearson D; Chan R; Thompson LC; Gabe R; Brada M; Stenning SP; Acta Neuropathol Commun; 2014 Jun; 2():68. PubMed ID: 24952577 [TBL] [Abstract][Full Text] [Related]
53. MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma. Lohkamp LN; Schinz M; Gehlhaar C; Guse K; Thomale UW; Vajkoczy P; Heppner FL; Koch A PLoS One; 2016; 11(6):e0156422. PubMed ID: 27253461 [TBL] [Abstract][Full Text] [Related]
54. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients. Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093 [TBL] [Abstract][Full Text] [Related]
55. Telomerase reverse transcriptase promoter mutation- and O Gramatzki D; Felsberg J; Hentschel B; Wolter M; Schackert G; Westphal M; Regli L; Thon N; Tatagiba M; Wick W; Schlegel U; Krex D; Matschke J; Roth P; Suresh MP; Kamp MA; Rushing EJ; Pietsch T; von Deimling A; Sabel M; Loeffler M; Weller M; Reifenberger G Eur J Cancer; 2021 Apr; 147():84-94. PubMed ID: 33631540 [TBL] [Abstract][Full Text] [Related]
56. Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas. Haque W; Thong E; Andrabi S; Verma V; Brian Butler E; Teh BS J Clin Neurosci; 2021 Mar; 85():115-121. PubMed ID: 33581781 [TBL] [Abstract][Full Text] [Related]
57. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region. Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342 [TBL] [Abstract][Full Text] [Related]
58. Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas. Gömöri E; Pál J; Kovács B; Dóczi T Diagn Pathol; 2012 Jan; 7():8. PubMed ID: 22264301 [TBL] [Abstract][Full Text] [Related]
59. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
60. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]